Italia markets closed

Biocartis Group NV (0R72.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
1,7340+0,0143 (+0,83%)
Alla chiusura: 05:40PM BST
Schermo intero
Chiusura precedente1,7197
Aperto1,7197
DenaroN/D x N/D
LetteraN/D x N/D
Min-Max giorno1,7200 - 1,7200
Intervallo di 52 settimane0,2865 - 1,7200
VolumeN/D
Media Volume75.678
CapitalizzazioneN/D
Beta (5 anni mensile)1,38
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Press release Biocartis Group NV: Biocartis 2023 half-year results webcast on 26 September 2023

    PRESS RELEASE REGULATED INFORMATION 21 September 2023, 07:00 CEST BIOCARTIS 2023 HALF-YEAR RESULTS WEBCAST ON 26 SEPTEMBER 2023 Mechelen, Belgium, 21 September 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), will report its 2023 half-year results and provide further updates on the status of its reorganization and financing & recapitalization plans on 26 September 2023 at 07:00 CEST. That day, Roger Moody, Biocartis

  • GlobeNewswire

    Press Release Biocartis Group NV: Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leaders

    PRESS RELEASE: 28 August 2023, 7:00 AM CEST Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leaders Mechelen, Belgium, 28 August 2023 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), is pleased to announce the appointment of a global Medical Advisory Board (MAB) comprised on renowned and influential KOLs in diagnostics, pharma and hospitals to advise, inform and guide Biocartis’ expedited global

  • GlobeNewswire

    Press Release Biocartis Group NV: Biocartis Announces 2023 Half-Year Results on 26 September 2023

    PRESS RELEASE: 24 August 2023, 07:00 CEST BIOCARTIS ANNOUNCES 2023 HALF-YEAR RESULTS ON 26 SEPTEMBER 2023 Mechelen, Belgium, 24 August 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today that it will report its 2023 half-year results and provide further updates on the status of its reorganization and financing & recapitalization plans on 26 September 2023, which is later than the previously communicated